Log in  First Connection?

Blood CancerArchives

Genetic insights into acute lymphoblastic leukemia: the role of MDR1 and IL18 polymorphisms in Egyptian children
Blood Cancer
 6 min.

 Published on 25/11/2025 |  Original article (Full-text)  | Mahdi Ali Nabeel et al. | BMC Cancer 2025; 25(1): 1790

Acute lymphoblastic leukemia (ALL) is a particularly aggressive form of hematopoietic cancer that is both physiologically diverse and clinically aggressive. The clonal proliferation and accumulation of immature lymphoid progenitor cells are the causes of this condition, which ultimately results in extensive...

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
Blood Cancer
 7 min.

 Published on 18/11/2025 |  Original article (Full-text)  | Van der Vreken Arne et al. | Journal of Hematology & Oncology 2025; 18(1): 103

Multiple myeloma (MM) is a plasma cell malignancy characterized by the abnormal accumulation of plasma cells primarily in the bone marrow (BM) [1]. This hematological malignancy is still considered incurable, mainly due to cellular heterogeneity and the development of therapy resistance. Recent advances...

WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1
Blood Cancer
 1 min.

 Published on 11/11/2025 |  Original article (Full-text)  | Han Xu * et al. | Leukemia & Lymphoma 2025; aop:10.1080/10428194.2025.2576561

Multiple myeloma (MM) remains incurable, largely owing to the lack of effective therapeutic targets. Wilms' tumor 1-associated protein (WTAP) has been implicated in MM tumorigenesis, but its underlying molecular mechanisms remain unclear. This study aimed to elucidate the role of WTAP in MM progression....

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Blood Cancer
 6 min.

 Published on 04/11/2025 |  Original article (Full-text)  | Boccadoro Mario et al. | BMC Cancer 2025; 25(1): 1674

Multiple Myeloma (MM) is a rare hematological tumor affecting B lymphocytes and is the second-most commonly diagnosed hematological malignancy in Europe [1]. In Italy, MM accounts for 1.5% of all diagnosed tumors, with an annual incidence of approximately 5,700 cases [2] and a median age at diagnosis...

Proceedings of the 4th European Congress controversies in Leukemias, held in Brussels, Belgium, 20-21 November, 2023.
Blood Cancer
 1 min.

 Published on 24/09/2024 |  Synthesis  | The ContentGeneMD editorial committee

AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...